Post-Scrip: The ASPL Pharmacy Law Podcast | S1E6 - Jeff Mesaros, PharmD, JD - Ro
Listen now
Description
Today we welcome Jeff Mesaros, PharmD, JD with Ro. Our host Henry Hine explores the fascinating journey Jeff has taken throughout his career, as well as unpacking the premise of his seminar topic entitled: "Test & Treat."  Pharmacy-based Test and Treat programs increase access to health care by allowing pharmacists to perform appropriate assessments and diagnostic tests and to treat patients based on the results of those tests. Throughout COVID-19, pharmacies have stepped up to close a gap in care and improve health equity throughout the United States. Many states lack the regulatory framework to continue this valuable patient care service in the absence of the PreP Act allowances. This program will serve to review the regulatory framework of Arkansas and Florida and provide lessons learned for other states to work with regulatory agencies to maintain this standard of care.  The 33rd annual American Society for Pharmacy Law Developments in Pharmacy Law seminar will be held November 3-6 at the Naples Grande Beach Resort in Naples, FL. The Seminar is being held in-person this year! Don't miss this opportunity to learn, share and network with seasoned legal and pharmaceutical professionals.  Attendees will have the opportunity to earn up to 15 hours of ACPE and CLE continuing education credits.  We look forward to having you join us in November!
More Episodes
In this episode of Post-Scrip, Henry introduces Jenni Wai, RPh. , MBA, Josh Bolin and Christopher R. Smith, JD, LLM. They discuss the upcoming "Regulatory, Industry and Legal Perspectives on the Future of the DSCSA".This presentation will provide an update on the final stages of implementation of...
Published 10/16/24
In this episode of Post-Scrip, Henry introduces Marty Allain, JD. They discuss the upcoming "How Drug Manufacturer Restrictions and Recent Court Decisions are Re-Shaping 340B Drug Distribution and Delivery Models".Pharmaceutical manufacturers continue to restrict the delivery of 340B drug...
Published 10/09/24